Nature Reviews Cardiology, Journal Year: 2021, Volume and Issue: 18(5), P. 368 - 379
Published: Jan. 18, 2021
Language: Английский
European Heart Journal, Journal Year: 2022, Volume and Issue: 43(40), P. 3997 - 4126
Published: Aug. 26, 2022
Vedran Velagic (Croatia), Sami Viskin (Israel)
Citations
1729
European Heart Journal, Journal Year: 2022, Volume and Issue: 43(27), P. 2549 - 2561
Published: April 15, 2022
Abstract Most patients survive acute myocardial infarction (MI). Yet this encouraging development has certain drawbacks: heart failure (HF) prevalence is increasing and affected tend to have more comorbidities worsening economic strain on healthcare systems impeding effective medical management. The heart’s pathological changes in structure and/or function, termed remodelling, significantly impact patient outcomes. Risk factors like diabetes, chronic obstructive pulmonary disease, female sex, others distinctly shape disease progression the ‘road HF’. Despite availability of HF drugs that interact with general pathways involved targeted remain absent, risk stratification poor. Hence, review, we highlight pathophysiological basis, current diagnostic methods available treatments for cardiac remodelling following MI. We further aim provide a roadmap developing improved novel interventional therapies.
Language: Английский
Citations
310
Cardiovascular Drugs and Therapy, Journal Year: 2020, Volume and Issue: 34(6), P. 849 - 863
Published: Sept. 9, 2020
Language: Английский
Citations
301
Circulation Research, Journal Year: 2021, Volume and Issue: 128(10), P. 1451 - 1467
Published: May 13, 2021
In accordance with the comorbidity-inflammation paradigm, comorbidities and especially metabolic are presumed to drive development severity of heart failure preserved ejection fraction through a cascade events ranging from systemic inflammation myocardial fibrosis. Recently, novel experimental clinical evidence emerged, which strengthens validity inflammatory/profibrotic paradigm. This consists among others (1) infiltration by immunocompetent cells not only because an obesity-induced load but also arterial hypertension-induced hemodynamic load. The latter is sensed components extracellular matrix like basal laminin, interact cardiomyocyte titin; (2) expression in cardiomyocytes inducible nitric oxide synthase circulating proinflammatory cytokines. results accumulation degraded proteins failing unfolded protein response; (3) definition machine learning algorithms phenogroups patients distinct signature; (4) direct coupling mediation analysis between comorbidities, inflammatory biomarkers, deranged structure/function endothelial adhesion molecules already apparent early preclinical (HF stage A, B). new paves road for future treatments such as biologicals directed against cytokines, stimulation ubiquitylation phosphodiesterase 1 inhibitors, correction titin stiffness natriuretic peptide-particulate guanylyl cyclase-PDE9 (phosphodiesterase 9) signaling molecular/cellular regulatory mechanisms that control
Language: Английский
Citations
218
Journal of the American College of Cardiology, Journal Year: 2022, Volume and Issue: 80(1), P. 22 - 32
Published: June 27, 2022
Language: Английский
Citations
148
Circulation, Journal Year: 2022, Volume and Issue: 145(10), P. 765 - 782
Published: Feb. 3, 2022
Recent studies have established that CCR2 (C-C chemokine receptor type 2) marks proinflammatory subsets of monocytes, macrophages, and dendritic cells contribute to adverse left ventricle (LV) remodeling heart failure progression. Elucidation the effector mechanisms mediate effects
Language: Английский
Citations
82
Cardiovascular Research, Journal Year: 2022, Volume and Issue: 118(18), P. 3536 - 3555
Published: Aug. 24, 2022
Abstract Many patients with symptoms and signs of heart failure have a left ventricular ejection fraction ≥50%, termed preserved (HFpEF). HFpEF is heterogeneous syndrome mainly affecting older people who many other cardiac non-cardiac conditions that often cast doubt on the origin symptoms, such as breathlessness, or signs, peripheral oedema, rendering them neither sensitive nor specific to diagnosis HFpEF. Currently, management directed at controlling treating comorbid hypertension, atrial fibrillation, anaemia, coronary artery disease. also characterized by persistent increase in inflammatory biomarkers. Inflammation may be key driver development progression its associated comorbidities. Detailed characterization pathways provide insights into pathophysiology guide future management. There growing interest novel therapies specifically designed target deregulated inflammation therapeutic areas, including cardiovascular However, large-scale clinical trials investigating effectiveness anti-inflammatory treatments are still lacking. In this manuscript, we review role possible implications for trials.
Language: Английский
Citations
74
Nutrients, Journal Year: 2023, Volume and Issue: 15(3), P. 591 - 591
Published: Jan. 23, 2023
Iron functions as an essential micronutrient and participates in normal physiological biochemical processes the cardiovascular system. Ferroptosis is a novel type of iron-dependent cell death driven by iron accumulation lipid peroxidation, characterized depletion glutathione suppression peroxidase 4 (GPX4). Dysregulation metabolism ferroptosis have been implicated occurrence development diseases (CVDs), including hypertension, atherosclerosis, pulmonary myocardial ischemia/reperfusion injury, cardiomyopathy, heart failure. chelators deferoxamine dexrazoxane, lipophilic antioxidants ferrostatin-1 liproxstatin-1 revealed to abolish suppress peroxidation other CVDs. Notably, inhibition has demonstrated alleviate cardiac impairments, fibrosis pathological remodeling during hypertension potentiating GPX4 signaling. Administration improved injury inhibiting peroxidation. Several small molecules may be effective treatment ferroptosis-mediated In this article, we summarize regulatory roles underlying mechanisms dysregulation Targeting are potential therapeutic strategies prevention
Language: Английский
Citations
64
Acta Pharmaceutica Sinica B, Journal Year: 2023, Volume and Issue: 13(5), P. 1919 - 1955
Published: Feb. 11, 2023
Chronic heart failure (CHF) is a severe public health problem with increasing morbidity and mortality, any treatment targeting single session insufficient to tackle this. CHF characterized by reduced cardiac output resulting from neurohumoral dysregulation remodeling, which might be related oxidative stress, inflammation, endoplasmic reticulum apoptosis, autophagy, mitochondrial function, angiogenesis. These molecular mechanisms interact each other through crosstalk. Historically, Chinese medicinal herbs have been widely applied in the of CHF, therapeutic effects their ingredients scientifically confirmed over past decades. Traditional medicine (TCM) multiple components can confront different pathogenesis targets. This review analyzes commonly used TCM patent drugs decoctions that are applicable stages based on clinical trials. Diverse bioactive found treat via mechanisms. comprehensively covers key works underlying TCM, herbal synergistic constituent compatibility treating providing additional ideas address this threat.
Language: Английский
Citations
56
Bioactive Materials, Journal Year: 2024, Volume and Issue: 42, P. 270 - 283
Published: Sept. 4, 2024
Language: Английский
Citations
27